BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis
(NASDAQ: ISO), the leader in functional single-cell
proteomics, today announced the appointment of Richard Rew as
Senior VP, General Counsel and Secretary; Raj Khakhar as VP of
Finance; and Manny Resendes as
Global Controller. These three new appointments further strengthen
Isoplexis' financial and legal teams.
"We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes
join our team at IsoPlexis," said Sean Mackay, CEO of
IsoPlexis. "These recent hires will strengthen our ability to
accelerate our growth trajectory and track record of innovation in
the life science industry. We are excited to welcome their
extensive knowledge and experience to the company as we enter this
next stage of growth."
Mr. Rew comes to IsoPlexis with nearly 15 years of experience in
the biotechnology industry. He previously served as Chief
Compliance Officer and Senior VP, General Counsel and Secretary at
Luminex Corporation, where he oversaw legal, compliance and
corporate development matters.
Before joining IsoPlexis, Mr. Khakhar served as Director of
Finance for the Corporate FP&A Team at Thermo Fisher
Scientific. Prior to that he was Senior Director of Finance at the
Lojack Corporation. With more than 20 years working in corporate
finance, Mr. Khakhar has helped companies grow, restructure, and
navigate mergers and acquisitions. His areas of expertise include
strategic planning, financial modeling, organizational restructure,
forecasting, commissions structuring, P&L, board relations and
driving shareholder value.
Mr. Resendes also comes to IsoPlexis with over 20 years of
accounting and finance experience. As Finance Director, Global
Instrument Operations at PerkinElmer, Inc., Mr. Resendes led a
finance and accounting team supporting seven manufacturing
facilities in Canada, China, Italy,
Singapore, the U.K. and the U.S.
His areas of expertise include cost accounting, budgeting,
financial reporting and development of internal management
reports.
About IsoPlexis
IsoPlexis is leading a new era of
functional proteomics. By identifying our most proteomically active
single cells (or "superhero cells") for the first time, IsoPlexis
enables researchers to connect more directly to in vivo biology and
develop more precise and personalized therapies. IsoPlexis has been
named Top Innovation or Design by The Scientist Magazine, Fierce,
BIG Innovation, Red Dot and multiple others. The IsoPlexis platform
is used globally by researchers, including those at the top 15
global pharmaceutical companies and at the majority of leading U.S.
comprehensive cancer centers.
Cautionary Note Regarding Forward Looking
Statements
Certain statements in this press release are
forward-looking statements that are subject to risks and
uncertainties that could cause results to be materially different
than expectations. Such statements can be identified by the use of
words such as "will". Important factors that could
cause actual results to differ materially include: the rate of
adoption of the Company's technology by its customers and potential
customers as well as the risk factors set forth in the Risk Factors
section of the Company's prospectus filed with the SEC. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, IsoPlexis disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Related Links
www.isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-appoints-key-financial-and-legal-hires-from-leading-tools-and-omics-companies-301433690.html
SOURCE IsoPlexis